A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
Clinical trial NCT02651662 · COMPLETED
Trial details
- NCT number
- NCT02651662
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-11
- Primary completion
- 2026-04-29
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.